Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Feltelius

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Annals of the Rheumatic Diseases|January 1, 1988
Circulating inhibitor bound elastase in patients with ankylosing spondylitis and rheumatoid arthritis and the influence of sulphasalazine treatmentN Feltelius, R Hällgren
Lakartidningen|April 11, 2001
[New drugs require nw follow-up surveillance]N Feltelius, S Lindblad
Annals of the Rheumatic Diseases|May 1, 1986
Sulphasalazine in ankylosing spondylitisN Feltelius, R Hällgren
Journal of Internal Medicine|December 21, 2016
Response to letter from Lars AnderssonI Persson, N Feltelius
The Journal of Rheumatology|February 1, 1988
Redistribution of cellular mineral and trace element stores in HLA-B27 positive relatives of patients with ankylosing spondylitis--a marker of hidden inflammatory diseaseN Feltelius, R Hällgren, U Lindh
The Journal of Rheumatology|June 1, 1987
Redistribution of minerals and trace elements in chronic inflammation--a study on isolated blood cells from patients with ankylosing spondylitisR Hällgren, N Feltelius, U Lindh
Annals of the Rheumatic Diseases|May 1, 1987
Raised circulating levels of the eosinophil cationic protein in ankylosing spondylitis: relation with the inflammatory activity and the influence of sulphasalazine treatmentN Feltelius, R Hällgren, P Venge
Annals of the Rheumatic Diseases|December 3, 2003
Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort studyN Feltelius, A Ekbom, P Blomqvist
Clinical Rheumatology|December 1, 1987
T lymphocytes in ankylosing spondylitis and the influence of sulphasalazine treatmentN Feltelius, R Hällgren, O Sjöberg
Alimentary Pharmacology & Therapeutics|April 4, 2001
A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactionsP Blomqvist, N Feltelius, R Löfberg, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Annals of the Rheumatic Diseases|January 1, 1988
Circulating inhibitor bound elastase in patients with ankylosing spondylitis and rheumatoid arthritis and the influence of sulphasalazine treatmentN Feltelius, R Hällgren
Lakartidningen|April 11, 2001
[New drugs require nw follow-up surveillance]N Feltelius, S Lindblad
Annals of the Rheumatic Diseases|May 1, 1986
Sulphasalazine in ankylosing spondylitisN Feltelius, R Hällgren
Journal of Internal Medicine|December 21, 2016
Response to letter from Lars AnderssonI Persson, N Feltelius
The Journal of Rheumatology|February 1, 1988
Redistribution of cellular mineral and trace element stores in HLA-B27 positive relatives of patients with ankylosing spondylitis--a marker of hidden inflammatory diseaseN Feltelius, R Hällgren, U Lindh
The Journal of Rheumatology|June 1, 1987
Redistribution of minerals and trace elements in chronic inflammation--a study on isolated blood cells from patients with ankylosing spondylitisR Hällgren, N Feltelius, U Lindh
Annals of the Rheumatic Diseases|May 1, 1987
Raised circulating levels of the eosinophil cationic protein in ankylosing spondylitis: relation with the inflammatory activity and the influence of sulphasalazine treatmentN Feltelius, R Hällgren, P Venge
Annals of the Rheumatic Diseases|December 3, 2003
Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort studyN Feltelius, A Ekbom, P Blomqvist
Clinical Rheumatology|December 1, 1987
T lymphocytes in ankylosing spondylitis and the influence of sulphasalazine treatmentN Feltelius, R Hällgren, O Sjöberg
Alimentary Pharmacology & Therapeutics|April 4, 2001
A 10-year survey of inflammatory bowel diseases-drug therapy, costs and adverse reactionsP Blomqvist, N Feltelius, R Löfberg, et al.
Pageof 4